

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



In re Applicant:

PECKER et al

Serial No.: 10/785,116

Filed: February 25, 2004

For: Polynucleotide Encoding A Polypeptide Having Heparanase Activity And Expression of Same in Genetically Modified Cells

Examiner: R. Hutson

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

[illegible]

Group Art Unit: 1652

Attorney
Docket: 27674

REQUEST FOR CORRECTED FILING RECEIPT

Sir:

Attached is a copy of the official filing receipt received from the United States Patent and Trademark Office in the above application. Issuance of a corrected filing receipt to correct an error of the USPTO is respectfully requested.

In the section entitled “Domestic Priority data as claimed by applicant”: please correct as follows:

“This application is a CON of 09/988,113 11/19/2001
which is a CON of 09/776,874 02/06/2001
which is a CON of 09/258,892 03/01/1999 ABN
which is a CIP of PCT/US98/17954 08/31/1998
which claims benefit from 09/109,386 07/02/1998 ABN
which is a CON of 08/922,170 09/02/1997 now 5,968,822”.

A copy of the first page of the Application, as amended by a preliminary amendment filed concurrently with the Application setting forth the above is attached hereto.

Applicant is concurrently filing an amendment with this response to properly show the relationship of the PCT Application and Application 09/109,386.

Respectfully submitted,

Sol Sheinbein
Registration No. 25,457

Date: April 20, 2005



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
 www.uspto.gov

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/785,116	02/25/2004	1652	672	27674	33	28	8

SOL SHEINBEIN
 c/o ANTHONY CASTORINA
 SUITE 207
 2001 JEFFERSON DAVIS HIGHWAY
 ARLINGTON, VA 22202

CONFIRMATION NO. 1402

FILING RECEIPT



OC000000012335720

Date Mailed: 04/12/2004

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Iris Pecker, Rishon LeZion, ISRAEL;
 Israel Vlodavsky, Mevaseret Zion, ISRAEL;
 Elena Feinstein, Rehovot, ISRAEL;

Domestic Priority data as claimed by applicant

This application is a CON of 09/988,113 11/19/2001
 which is a CON of 09/776,874 02/06/2001
 which is a CON of 09/258,892 03/01/1999 ABN
 which is a CIP of PCT/US98/17954 08/31/1998

Foreign Applications

If Required, Foreign Filing License Granted: 04/12/2004

Projected Publication Date: 07/22/2004

Non-Publication Request: No

Early Publication Request: No

** SMALL ENTITY **

Title

Polynucleotide encoding a polypeptide having heparanase activity and expression of same in genetically modified cells

Preliminary Class

435

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

**In the Specification:**

Replace the paragraphs beginning at page 1, line 15, with the following rewritten paragraph:

RELATED PATENT APPLICATIONS

This is a continuation of U.S. Patent Application No. 09/988,113, filed November 19, 2001, which is a continuation of U.S. Patent Application No. 09/776,874, filed February 6, 2001, which is a continuation of U.S. Patent Application No. 09/258,892, filed March 1, 1999, which is a continuation-in-part of PCT/US98/17954, filed August 31, 1998, which claims priority from U.S. Patent Application 09/109,386, filed July 2, 1998, now abandoned, which is a continuation-in-part of U.S. Patent Application 08/922,170, filed September 2, 1997, now, U.S. Patent No. 5,968,822.

Please amend pages 50, 51, 52, 112 as follows:

Replace the paragraph beginning at page 50, line 20, with the following rewritten paragraph:

FIG. 16 presents the nucleotide sequence of the genomic region of the *hpa* gene with regard to SEQ ID NO: 42. Exon sequences appear in upper case and intron sequences in lower case. The deduced amino acid sequence of the exons is printed below the nucleotide sequence. Two predicted transcription start sites are shown in bold.

Replace the paragraph beginning at page 51, line 3, with the following rewritten paragraph: